Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?

Circulation

Volumn 100, Issue 4, 1999, Pages 437-444

  Scarborough, Robert M ^a   Kleiman, Neal S ^b   Phillips, David R ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angina; Angioplasty; Pharmacology; Platelet aggregation inhibitors; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CD11B ANTIGEN; CD18 ANTIGEN; COLLAGEN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; LAMIFIBAN; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; THROMBOCYTE RECEPTOR; TIROFIBAN; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR;

ANGINA PECTORIS; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0033609537     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.4.437     Document Type: Review

References (72)

1. Davies MJ. Pathology of arterial thrombosis. Br Med Bull. 1994;50: 789-802.
2. Phillips DR, Charo IF, Scarborough RM. GP IIb/IIIa. The responsive integrin. Cell. 1991;65:359-362.
3. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211-218.
4. Mousa SA, Bennett JS. Platelets in health and disease: platelet GP IIb/IIIa structure and function: recent advances in antiplatelet therapy. Drugs Future. 1996;21:1141-1154.
5. Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future. 1994;19:135-159.
6. Zablocki JA, Nicholson NS, Feigen LP. Fibrinogen receptor antagonists. Exp Opin Invest Drugs. 1994;3:437-448.
7. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J. 1996;17:9-18.
8. Robinson C. Abciximab. Drugs Future. 1995;20:457-463.
9. Jordan RE, Wagner CL, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, Fla: CRC Press; 1996: 281-305.
10. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996;78(suppl 3A):35-40.
11. Coller BS. GP IIb/IIIa antagonists. Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730-735.
12. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
13. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998;98:2629-2635.
14. Kieffer N, Fitzgerald LA, Wolf D, Cheresh DA, Phillips DR. Adhesive properties of the beta 3 integrins: comparison of GP IIb/IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol. 1991;113:451-461.
15. Gawaz MP, Loftus JC, Bajt ML, Frojmovic MM, Plow EF, Ginsberg MH. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GP IIB/IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest. 1991;88:1128-1134.
16. Byzova TV, Plow EF. Networking in the hemostatic system. J Biol Chem. 1997;272:27183-27188.
17. Wencel-Drake JD, Plow EF, Kunicki TJ, Woods VL, Keller DM, Ginsberg MH. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol. 1986;124:324-334.
18. Reverter J, Beguin S, Kessels R, Hemker H, Coller B. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 1996;98:863-874.
19. Wagner CL, Macelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907-914.
20. Woods VL Jr, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb/IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem. 1986;261:15242-15251.
21. Montgomery R, Coller B. Von Willebrand disease. In: Colman R, Hirsh J. Marder V, Salzman E, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott; 1994:134-168.
22. Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci U S A. 1992;89:10729-10732.
23. 3. EMBO J. 1996;15:5760-5771.
24. Nies AS. Principles of therapeutics. In: Gilman AG, Rall TW, Nies, AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1993:62-83.
25. Wagner C, Mace K, Mascelli MA, DeRita R, Weisman H, Ghrayeb J, Jordan R. Pharmacodynamics of ReoPro (c7E3 fab): free plasma levels determine clinical efficacy. Thromb Haemost. 1997;78(suppl):7. Abstract.
26. Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJMC, Slee AM, Reilly TM, Friedman PA. Antiplatelet efficacy of XV459, a novel nonpeptide GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther. 1998;256:1277-1284.
27. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody FAB 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
28. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373-2380.
29. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
30. Prueksaritanont T, Gorham LM, Naue JA, Hamill TG, Askew BC, Vyas KP. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Drug Metab Dispos. 1997;25:355-361.
31. Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ Jr. Nonpeptide glycoprotein IIb/IIIa Inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GP IIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not bleeding time prolongation. J Pharmacol Exp Ther. 1997;281: 677-689.
32. Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observation on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb/IIIa. Blood Coagul Fibrinolysis. 1993;4:729-737.
33. Bednar RA, Bednar B, Gaul SL, Chang CT, Hamill T, Egbertson MS, Halxzenko W, Hartman GD, Schafer JA, Gould RJ. Binding of the fibrinogen receptor antagonist MK-0383 to purified GP IIb/IIIa and to platelets. FASEB J. 1995;9:A56. Abstract.
34. Reiderer MA, Steiner B. The extent of platelet aggregation is dependent on the free GP IIb/IIIa concentration and not the % receptor occupancy. Thromb Haemost. 1997;78(suppl):6. Abstract.
35. Bednar B, Cunningham ME, McQueney PA, Egbertson MA, Askew BC, Bednar RA, Hartman GD, Gould RJ. Flow cytometric measurements of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding to glycoprotein IIb/IIIa on platelets. Cytometry. 1997;28:58-65.
36. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff M, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76: 1222-1227.
37. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ, for the EPIC Investigators. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol. 1994;74:1166-1170.
38. Gammie JS, Zenati M, Kormos RL, Hattler BG, Wei LM, Pellegrini RV, Griffith BP, Dyke CM. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg. 1998;65: 465-469.
39. Frelinger AL III, Lam SC-T, Plow EF, Smith MA, Loftus JC, Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem. 1988;263:12397-12402.
40. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539-2547.
41. Murphy NP, Pratico D, Fitzgerald DJ. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. J Pharmacol Exp Ther. 1998;286:945-951.
42. 2+ signaling. Blood. 1998;92: 3675-3683.
43. 3) inhibitors. Blood. 1998;92:3240-3249.
44. Cines DB. Glycoprotein GP IIb/IIIa antagonists. Potential induction and detection of drug-dependent antiplatelet antibodies. Am Heart J. 1998; 135:S152-S159.
45. 3 on platelets. Mol Biol Cell. 1996;7:247a. Abstract.
46. Charo IF, Fitzgerald LA, Steiner B, Rall SC Jr, Bekeart LS, Phillips DR. Platelet glycoproteins IIb, and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci U S A. 1986;83:8351-8355.
47. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-535.
48. 3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995;74:149-155.
49. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203-2206.
50. 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79: 1157-1164.
51. Mogford JE, Davis GE, Platts SH, Meininger GA. Vascular smooth muscle avb3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res. 1996;79:821-826.
52. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;90:956-961.
53. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
54. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996;28: 1643-1651.
55. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
56. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
57. Deitch JS, Williams JK, Adams MR, Fly CA, Herrington DM, Jordan RE, Nakada MT, Jakubowski JA, Geary RL. Effects of β3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates. Arterioscler Thromb Vasc Biol. 1998; 18:1730-1737.
58. Coller BS. Monitoring of platelet GP IIb/IIIa antagonist therapy. Circulation. 1997;96:3828-3832.
59. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Amout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist in healthy men. Clin Pharmacol Ther. 1994;56:377-388.
60. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriquez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-542.
61. ++ on GP IIb/IIIa interactions with integrilin: enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reduction in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
62. Bednar B, Bednar RA, McQueney PA, Cunningham ME, Lynch RJ, Gaul SL, Egbertson MS, Hartman GD, Gould RJ. The effect of variability in the concentration of receptors and binding affinity of fibrinogen receptor antagonist on efficacy. Thromb Haemost. 1997;78(suppl):661. Abstract.
63. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
64. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
65. Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GP IIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 1994;71:95-102.
66. Theroux P, Kouz M, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault J-R, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, on behalf of the investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban study. Circulation. 1996;94:899-905.
67. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E, for the TIMI 12 Investigators: randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-349.
68. Vorcheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation. 1998;97: 312-314.
69. Scarborough RM. Eptifibatide. Drugs Future. 1998;23(6):585-590.
70. Tcheng JE, Thel MC, Jennings L, Joseph D, Caud TL, Talley JD, Kleiman NS, Gilchrist IC, Lorenz T, Kitt MM. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose integrilin in coronary intervention: results of the PRIDE Study. Eur Heart J. 1997;18(suppl):624. Abstract.
71. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PF, and the European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
72. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Hermann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-542.